Following these considerations, we have designed a triple activator of FXR, PPARα, and PPARδ to join the pharmacodynamic effects of the leading anti-NASH drug candidates OCA (1) and elafibranor (4). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.